Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19.
Campos-Murguía A, Román-Calleja BM, Toledo-Coronado IV, González-Regueiro JA, Solís-Ortega AA, Kúsulas-Delint D, Cruz-Contreras M, Cruz-Yedra N, Cubero FJ, Nevzorova YA, Martínez-Cabrera CF, Moreno-Guillén P, Lozano-Cruz OA, Chapa-Ibargüengoitia M, Gulías-Herrero A, Aguilar-Salinas CA, Ruiz-Margáin A, Macías-Rodríguez RU.
Campos-Murguía A, et al. Among authors: cruz contreras m.
Dig Liver Dis. 2021 May;53(5):525-533. doi: 10.1016/j.dld.2021.01.019. Epub 2021 Feb 2.
Dig Liver Dis. 2021.
PMID: 33551355
Free PMC article.